GlassScriptPhysician profile
Sarah A Devine-Cooter
NPI 1023406675
$2,916.08
in general payments reported to CMS, 2019-2025
17 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $934 · 2023: $963 · 2024: $398 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $420.96 | 2023-2025 | Impella |
| Edwards Lifesciences Corporation | $375.11 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $319.66 | 2022-2023 | Andexxa |
| Abbvie INC. | $249.52 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.96 | 2023-2024 | |
| Si-Bone, INC. | $144.13 | 2023 | |
| Amgen INC. | $142.86 | 2025 | Krystexxa |
| Hologic Sales and Service, LLC | $127.71 | 2024 | Aptima |
| Actelion Pharmaceuticals US, INC. | $125.17 | 2023 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $124.94 | 2022 | |
| Alkermes, INC. | $124.89 | 2025 | Lybalvi |
| Regeneron Healthcare Solutions, INC. | $121.82 | 2022 | |
| Neurocrine Biosciences, INC. | $118.46 | 2022 | |
| Biogen, INC. | $98.09 | 2023 | Spinraza |
| Hydrofera LLC | $91.41 | 2023 | Hydrofera Blue |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $85.33 | 2021 | |
| Ucb, INC. | $53.06 | 2024 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Devine-Cooter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.